替拉扎特 | 110101-66-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: 替拉扎特
• 英文名称: 16α-methyl-21-[4-[2,6-bis(1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]-pregna-1,4,9(11)-triene-3,20-dione
• 英文别名: Tirilazad；21-[4-(2,6-dipyrrolidinyl-4-pyrimidinyl)-16α-piperazinyl]-16α-methylpregna-1,4,9(11)-triene-3,20-dione；16α-methyl-21-[4-[2,6-bis (pyrrolidino)-4-pyrimidinyl]-1-piperazinyl]pregna-1,4,9(11)-triene-3,20 dione；(8S,10S,13S,14S,16R,17S)-17-[2-[4-(2,6-dipyrrolidin-1-ylpyrimidin-4-yl)piperazin-1-yl]acetyl]-10,13,16-trimethyl-6,7,8,12,14,15,16,17-octahydrocyclopenta[a]phenanthren-3-one
• CAS: 110101-66-1
• 化学式: C₃₈H₅₂N₆O₂
• 分子量: 624.87
• InChiKey: RBKASMJPSJDQKY-RBFSKHHSSA-N

物化性质

• 沸点：
  812.9±75.0 °C(Predicted)
• 密度：
  1.25±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  46
• 可旋转键数：
  6
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.68
• 拓扑面积：
  72.9
• 氢给体数：
  0
• 氢受体数：
  8

ADMET

代谢

替利拉扎德已知的人体代谢物包括：(8S,10R,13S,14S,16R,17S)-17-[2-[4-(2,6-二吡咯烷-1-基嘧啶-4-基)哌嗪-1-基]乙酰基]-6-羟基-10,13,16-三甲基-6,7,8,12,14,15,16,17-八氢环戊[a]菲-3-酮，17-[2-[4-(2,6-二吡咯烷-1-基嘧啶-4-基)哌嗪-1-基]乙酰基]-6-羟基-10,13,16-三甲基-6,7,8,12,14,15,16,17-八氢环戊[a]菲-3-酮，17-[2-[4-[6-(3-羟基吡咯烷-1-基)-2-吡咯烷-1-基嘧啶-4-基]哌嗪-1-基]乙酰基]-10,13,16-三甲基-6,7,8,12,14,15,16,17-八氢环戊[a]菲-3-酮，以及17-[2-[4-[2-(3-羟基吡咯烷-1-基)-6-吡咯烷-1-基嘧啶-4-基]哌嗪-1-基]乙酰基]-10,13,16-三甲基-6,7,8,12,14,15,16,17-八氢环戊[a]菲-3-酮。

Tirilazad has known human metabolites that include (8S,10R,13S,14S,16R,17S)-17-[2-[4-(2,6-dipyrrolidin-1-ylpyrimidin-4-yl)piperazin-1-yl]acetyl]-6-hydroxy-10,13,16-trimethyl-6,7,8,12,14,15,16,17-octahydrocyclopenta[a]phenanthren-3-one, 17-[2-[4-(2,6-dipyrrolidin-1-ylpyrimidin-4-yl)piperazin-1-yl]acetyl]-6-hydroxy-10,13,16-trimethyl-6,7,8,12,14,15,16,17-octahydrocyclopenta[a]phenanthren-3-one, 17-[2-[4-[6-(3-hydroxypyrrolidin-1-yl)-2-pyrrolidin-1-ylpyrimidin-4-yl]piperazin-1-yl]acetyl]-10,13,16-trimethyl-6,7,8,12,14,15,16,17-octahydrocyclopenta[a]phenanthren-3-one, and 17-[2-[4-[2-(3-hydroxypyrrolidin-1-yl)-6-pyrrolidin-1-ylpyrimidin-4-yl]piperazin-1-yl]acetyl]-10,13,16-trimethyl-6,7,8,12,14,15,16,17-octahydrocyclopenta[a]phenanthren-3-one.

来源:NORMAN Suspect List Exchange

制备方法与用途

替利拉扎德是一种非糖皮质激素的21氨基类固醇，能够抑制脂质过氧化。它能减轻创伤、中风、缺血和再灌注损伤引起的脑或脊髓损伤，并且对nCoV具有抗病毒活性。此外，替利拉扎德在缺血性中风中具有神经保护作用，可用于蛛网膜下腔出血的研究[1][2][3]。

反应信息

• 作为反应物：
  描述：

  、 替拉扎特 、 21-(4-(2,6-二-1-吡咯烷基-4-嘧啶基)-1-哌嗪基)-16-甲基孕甾-1,4,9(11)-三烯-3,20-二酮单甲烷磺酸盐 、 16alpha-Methyl-21-[4-[2,6-bis(1-pyrrolidinyl)-4pyrimidinyl]-1-piperazinyl]pregna1,4,9(11)-triene-3,20-dione bismethanesulfonate 、 16alpha-Methyl-21-[4-[2,6-bis(1-pyrrolidinyl)-4-pyrimidinyl]-1-piperazinyl]pregna-1,4,9(11)-triene-3,20-dione hydrochloride 生成 21-[4-[6-(Ethylamino)-2-pyridinyl]piperazinyl]-16alpha-methylpregna-1,4,9(11)-triene-3,20-dione
  参考文献：
  名称：

  Triazinylpiperazinyl steroids

  摘要：

  本发明涉及一种氨基取代类固醇（XI），其包含连接到C.sub.17-侧链末端碳原子的4-[1,3,5-三嗪基]-或4-[1,2,4-三嗪基]-1-哌嗪基团，这些类固醇可用作治疗多种疾病的药物。

  公开号：

  US05380840A1
• 作为产物：
  描述：

  2,4-di(1-pyrrolidinyl)-6-chloropyrimidine 在 吡啶 、 potassium carbonate 、 sodium iodide 作用下， 以 乙腈 为溶剂， 反应 92.0h， 生成 替拉扎特
  参考文献：
  名称：

  Novel 21-aminosteroids that inhibit iron-dependent lipid peroxidation and protect against central nervous system trauma

  摘要：

  A novel class of 21-aminosteroids has been developed. Compounds within this series are potent inhibitors of iron-dependent lipid peroxidation in rat brain homogenates with IC50's as low as 3 microM. Furthermore, selected members enhance early neurological recovery and survival in a mouse head injury model. Significant improvement in the 1 h post-head-injury neurological status (grip test score) by as much as 168.6% of the control has been observed. The most efficacious compound in this assay (30) showed an increase in the 1-week survival of 78.6% as compared to 27.3% for the vehicle-treated mice in the head-injury model. Based on its biological profile, 21-[4-(2,6-di-1-pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl]-16 alpha- methylpregna-1,4,9(11)-triene-3,20-dione monomethanesulfonate (30) was selected for further evaluation and is currently entering phase I clinical trials for the treatment of head and spinal trauma.

  DOI：

  10.1021/jm00166a010

文献信息

• [EN] PYRAZOLO [4, 3-D] PYRIMIDINES USEFUL AS KINASE INHIBITORS<br/>[FR] PYRAZOLO[4,3-D]PYRIMIDINES UTILES EN TANT QU'INHIBITEURS DE KINASES
  申请人：ORIGENIS GMBH

  公开号：WO2012143144A1

  公开（公告）日：2012-10-26

  The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

  本发明涉及一种能够抑制一个或多个激酶，特别是SYK（脾酪氨酸激酶）、LRRK2（富含亮氨酸重复的激酶2）和/或MYLK（肌球蛋白轻链激酶）或其突变体的化合物的新颖化合物（I）的公式。这些化合物在治疗各种疾病中发挥作用。这些疾病包括自身免疫疾病、炎症性疾病、骨疾病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼部疾病、传染病和与激素相关的疾病。
• [EN] HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES EN TANT QU'INHIBITEURS DE KINASES
  申请人：ORIGENIS GMBH

  公开号：WO2012143143A1

  公开（公告）日：2012-10-26

  The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

  本发明涉及一种能够抑制一个或多个激酶，特别是SYK（脾酪氨酸激酶）、LRRK2（富含亮氨酸重复激酶2）和/或MYLK（肌球蛋白轻链激酶）或其突变体的化合物的新颖化合物（I）的公式。这些化合物在治疗各种疾病中发挥作用。这些疾病包括自身免疫疾病、炎症性疾病、骨疾病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼部疾病、传染病和与激素相关的疾病。
• [EN] N-ARYL AND N-HETEROARYL PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR β AGONISTS, COMPOSITIONS, AND THEIR USE<br/>[FR] DÉRIVÉS DE N-ARYLE ET DE N-HÉTÉROARYLE PIPÉRIDINE EN TANT QU'AGONISTES DES RÉCEPTEURS HÉPATIQUES X, COMPOSITIONS ET LEUR UTILISATION
  申请人：MERCK SHARP & DOHME

  公开号：WO2018068297A1

  公开（公告）日：2018-04-19

  Provided herein are certain substituted N-aryl and N-heteroaryl piperidine compounds of the formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, L, R4, L1, Q, R5 and R 6 are as defined. The said novel compounds, and pharmaceutically acceptable compositions comprising a compound thereof, may be useful as Liver X-β receptor(LXRβ) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory disease and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.

  提供的是某些取代的N-芳基和N-杂芳基哌啶化合物，其化学式为(I)以及药用可接受的盐，其中R1、R2、R3、L、R4、L1、Q、R5和R6定义如所述。所述新颖化合物，以及包含其化合物的药用可接受组合物，可能用作肝X-β受体(LXRβ)激动剂，并可用于治疗或预防与之相关的病理学。这类病理学包括但不限于炎症性疾病和以胆固醇和脂质代谢缺陷为特征的疾病，例如阿尔茨海默病。
• EPHA4 RTK INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISORDERS AND CANCER
  申请人：Nantermet Philippe G.

  公开号：US20100197688A1

  公开（公告）日：2010-08-05

  The present invention is directed to compounds of generic formula (I) which are inhibitors of ephrin A4. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases regulated by the EphA4 RTK signaling, such as neurological and neurodegenerative disorders and cancer.

  本发明涉及通式（I）的化合物，这些化合物是ephrin A4的抑制剂。该发明还涉及包含这些化合物的药物组合物，以及在治疗由EphA4 RTK信号调节的疾病中使用这些化合物和组合物，例如神经系统和神经退行性疾病以及癌症。
• [EN] BISPIPERIDINYL DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE<br/>[FR] DÉRIVÉS DE BISPIPÉRIDINYLE UTILISÉS COMME AGONISTES DES RÉCEPTEURS BÊTA X DU FOIE, COMPOSITIONS ASSOCIÉES ET LEUR UTILISATION
  申请人：MERCK SHARP & DOHME

  公开号：WO2017083219A1

  公开（公告）日：2017-05-18

  In its many embodiments, the present invention provides certain substituted bispiperidinyl compounds of the Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, L, R4, Q and R5 are as defined herein. The novel compounds of the invention, and pharmaceutically acceptable compositions comprising a compound thereof, are useful as Liver X-β receptor (LXRβ) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.

  在其多种实施方式中，本发明提供了以下式（I）的某些取代双哌啶基化合物及其药学上可接受的盐，其中R1、R2、R3、L、R4、Q和R5如本文所定义。本发明的新化合物及包括其化合物的药学上可接受的组合物可用作肝X-β受体（LXRβ）激动剂，并且可能用于治疗或预防与之相关的病理。这些病理包括但不限于炎症性疾病和以胆固醇和脂质代谢缺陷为特征的疾病，如阿尔茨海默病。